Clinical trial
Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of…
NCT00116649 · Graceway Pharmaceuticals, LLC, Industry · Completed
Key facts
| NCT number | NCT00116649 |
|---|---|
| Title | Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis |
| Official title | Open-Label Safety and Pharmacokinetic Study of AldaraTM (Imiquimod) Cream, 5% for One, Two, or Three Treatment Cycles to Surface Areas Greater Than 25 cm2 With Actinic Keratosis |
| Lead sponsor | Graceway Pharmaceuticals, LLC, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Keratosis |
| Intervention type | Drug |
| Interventions | imiquimod cream |
| Enrollment | 551 |
| Start date | Jun 1, 2005 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Jul 1, 2005 |
| Last update posted | Jul 20, 2010 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: